Document is current
Any future updates will be listed below
-
Authors
Singh, Vijay K. https://orcid.org/0000-0003-4872-4545
Almpani, Marianna
Maura, Damien
Kitao, Tomoe https://orcid.org/0000-0003-1366-4861
Ferrari, Livia
Fontana, Stefano
Bergamini, Gabriella
Calcaterra, Elisa
Pignaffo, Chiara
Negri, Michele
de Oliveira Pereira, Thays
Skinner, Frances https://orcid.org/0000-0002-4615-2048
Gkikas, Manos https://orcid.org/0000-0002-3753-6760
Andreotti, Danielle
Felici, Antonio
Déziel, Eric
Lépine, Francois
Rahme, Laurence G. https://orcid.org/0000-0002-5374-4332
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI134857)
Massachusetts General Hospital Research Scholar Award
- License Information
-
More Information
Article History
Received: 21 March 2022
Accepted: 19 August 2022
First Online: 30 August 2022
Competing interests
: L.G.R. has a financial interest in Spero Therapeutics, a company developing therapies to treat bacterial infections. L.G.R.’s financial interests are reviewed and managed by Massachusetts General Hospital and Mass General Brigham Integrated Health Care System in accordance with their conflict-of-interest policies. No funding was received from Spero Therapeutics and had no role in study design, data collection, analysis, interpretation, or the decision to submit the work for publication. The remaining authors declare no competing interests. Patent: Broad Sepctrum anti-virulence anti-persistence compounds. Inventors: Laurence Rahme, Francois Lepine, Damien Maura, Carmella Napolitano, Antonio Felice, Michele Negri, Stefano Fontana, Daniele Andreotti. Institution: Massachusetts General Hospital. Publication number: 20210130306. Filed October 19, 2018. Publication date: May 6, 2021. All compounds reported in this publication are included in the aforementioned patent.
